Inceptionr LLC Purchases Shares of 26,378 ADMA Biologics, Inc. (NASDAQ:ADMA)

Inceptionr LLC purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 26,378 shares of the biotechnology company’s stock, valued at approximately $452,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund grew its position in ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after acquiring an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in ADMA Biologics during the third quarter valued at approximately $61,858,000. EWG Elevate Inc. bought a new position in ADMA Biologics during the fourth quarter valued at approximately $480,000. Citigroup Inc. grew its position in ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after acquiring an additional 277,138 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Up 0.7 %

Shares of ADMA Biologics stock opened at $17.02 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52-week low of $5.88 and a 52-week high of $23.64. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of 60.79 and a beta of 0.60. The company’s 50 day moving average price is $16.66 and its 200-day moving average price is $17.96.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.